(PR-inside.com) - Oriel Therapeutics announced that effective immediately Richard (Rick) Fuller, M.D., a former senior executive at GlaxoSmithKline, has joined Oriel as Chief Executive Officer. Dr. Fuller brings 30 years of experience in the healthcare field. During his career he headed development programs leading to the approval and launch of important respiratory care products, including Serevent(R) and Advair(R). James Niedel, M.D., Ph.D., Executive Chairman of Oriel and Managing Director at New Leaf Venture Partners, said, 'We are fortunate to attract someone of Rick's background and stature to Oriel. His extensive knowledge of respiratory markets and product development will be critical ..
More...
More...